middle.news
Mesoblast’s Ryoncil® Surpasses US$115M Annual Revenue with Strong Pediatric Demand
9:57am on Friday 10th of July, 2026 AEST
•
Healthcare
Read Story
Mesoblast’s Ryoncil® Surpasses US$115M Annual Revenue with Strong Pediatric Demand
9:57am on Friday 10th of July, 2026 AEST
Key Points
Ryoncil® Q4 net revenue hits US$36 million
Full-year revenue totals US$115 million, beating projections
Strong demand in US pediatric steroid-refractory acute graft-versus-host disease
Capital structure strengthened by recent five-year credit facility
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mesoblast (ASX:MSB)
OPEN ARTICLE